alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.1SECTION 1350 CERTIFICATION     I, Julie Smolyansky, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Lifeway Foods, Inc.(the “Company”) on Form 10-QSB for three-month period endedJune 30, 2006:     (1) Fully complies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and     (2) That the information contained in the report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.     This written statement is being furnished to the Securities and Exchange Commission as anexhibit to such Form 10-QSB. A signed original of this written statement required by Section 906has been provided to the Company and will be retained by the Company and furnished to theSecurities and Exchange Commission or its staff upon request.Date: August 14, 2006       /s/ Julie Smolyansky     Julie Smolyansky, Chief Executive Officer,    President, and Director
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6320 AC-powered medical examination light. ( a ) *Identification.* An AC-powered medical examination light is an AC-powered device intended for medical purposes that is used to illuminate body surfaces and cavities during a medical examination.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 61 FR 1123, Jan. 16, 1996; 66 FR 38806, July 25, 2001]
## F IFTH 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________ Case No. 5D22- 1235 LT Case No. 2008

- CF

- 1683 -A

_____________________________ R OBERT W ILLIAM J ARDIN , Appella nt,
v. S TATE OF F LORIDA , Appellee
.

_____________________________ On appeal from the Circuit Court for Hernando County. Daniel B. Merritt, Jr., Judge. Matthew J. Metz, Public Def ender, and Ryan M. Belanger, Assistant Public Defender, Daytona Bea ch, for Appellant. Ashley M oody, Attorney General, Talla hassee, and Rebecca Rock McGuigan, Assistant Attorney Gen eral, Daytona Bea ch, for Appellee. Octo ber 1 0, 20 23
P ER C URIAM . A FFIRMED . M AKAR , E ISNAUGLE , and M AC I VER , J J., concur.2 _____________________________ Not final until disposition of any timely and authorized motion under Fla. R. App. P. 9.330 or 9.331 .

_____________________________
EXHIBIT 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                       ARMANINO FOODS OF DISTINCTION, INC.
                       PURSUANT TO 18 U.S.C. SECTION 1350


     I hereby certify that, to the best of my knowledge, the Quarterly Report
on Form 10-QSB of Armanino Foods of Distinction, Inc. for the period ending
September 30, 2004:

     (1) complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

     (2) the information contained in the Report fairly presents, in all
material aspects, the financial condition and results of operations of
Armanino Foods of Distinction, Inc.





/s/ William J. Armanino
William J. Armanino
Chief Executive Officer
November 12, 2004


A signed original of this written statement required by Section 906 of the
Sarbanes-Oxley Act of 2002 has been provided to Armanino Foods of Distinction,
Inc. and will be retained by Armanino Foods of Distinction, Inc. and furnished
to the Securities and Exchange Commission upon request.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1500 Enflurane gas analyzer. ( a ) *Identification.* An enflurane gas analyzer is a device intended to measure the concentration of enflurane anesthetic in a gas mixture.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1400 Pyrophyllite. ( a ) *Identity.* ( 1 ) The color additive pyrophyllite is a naturally occurring mineral substance consisting predominantly of a hydrous aluminum silicate, Al2O3·4SiO2·H2 O, intimately mixed with lesser amounts of finely divided silica, SiO2. Small amounts, usually less than 3 percent, of other silicates, such as potassium aluminum silicate, may be present. Pyrophyllite may be identified and semiquantitatively determined by its characteristic X-ray powder diffraction pattern and by its optical properties.
( 2 ) Color additive mixtures made with pyrophyllite are limited to those listed in this subpart as safe and suitable in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* Pyrophyllite shall conform to the following specifications: Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million.
Lead and arsenic shall be determined in the solution obtained by boiling 10 grams of the pyrophyllite for 15 minutes in 50 milliliters of 0.5*N* hydrochloric acid.
( c ) *Uses and restrictions.* Pyrophyllite may be safely used in amounts consistent with good manufacturing practice to color drugs that are to be externally applied.
( d ) *Labeling requirements.* The labeling of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
FIFTH DISTRICT COURT OF APPEAL

STATE OF FLORIDA

_____________________________ 

Case No. 5D22-1235 

LT Case No. 2008-CF-1683-A 

_____________________________ 

ROBERT WILLIAM JARDIN, 

Appellant, 

v.

STATE OF FLORIDA, 

Appellee. 

_____________________________ 

On appeal from the Circuit Court for Hernando County. 

Daniel B. Merritt, Jr., Judge. 

Matthew J. Metz, Public Defender, and Ryan M. Belanger, 

Assistant Public Defender, Daytona Beach, for Appellant. 

Ashley Moody, Attorney General, Tallahassee, and Rebecca Rock 

McGuigan, Assistant Attorney General, Daytona Beach, for 

Appellee. 

October 10, 2023 

PER CURIAM.

AFFIRMED. 

MAKAR, EISNAUGLE, and MACIVER, JJ., concur. 
2

_____________________________

Not final until disposition of any timely and 

authorized motion under Fla. R. App. P. 9.330 or 

9.331.

_____________________________
#### John M. Wells *v.*Liquor Control Commission

*Robert A. Slavitt,*for the law firm of Slavitt and Connery.

*Stephen J. O’Neill,*assistant attorney general, for the appellee (defendant).

Argued January 7

decided January 7, 1969

The motion by the law firm of Slavitt and Connery to withdraw its appearance for the plaintiff in the appeal from the Court of Common Pleas in Hartford County is granted.
**REGULATORY EVALUATION**

**Directorate Identifier:** 2011

- NM

- 1 11

- AD

**Executive Order 12866:** Could the AD be considered a “significant regulatory action”? YES ( ) explain NO (X) **DOT Regulatory Policies and Procedures:** Is the AD significant? YES ( ) explain NO (X) **Regulatory Flexibility Act:** Will the AD have a significant economic impact on a substantial number of small entities? YES ( ) explain NO (X) **Intrastate Aviation in Alaska:** This AD could affect intrastate aviation in Alaska. I s it appropriate t o include specific requirements for aircraft operated in Alaska, where aviation might be the only mode of transportation? YES ( ) explain NO (X)
Exhibit 35.1






ANNUAL STATEMENT OF COMPLIANCE

Reference
is hereby made to that certain Pooling and Servicing Agreement dated as of August 1, 2015, by and among DEUTSCHE MORTGAGE &
ASSET RECEIVING CORPORATION, as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, CWCAPITAL ASSET MANAGEMENT
LLC, as Special Servicer, LNR PARTNERS, LLC, as Special Servicer, WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee, DEUTSCHE
BANK TRUST COMPANY AMERICAS, as Certificate Administrator, Paying Agent and Custodian, and PENTALPHA SURVEILLANCE LLC, as Operating
Advisor with respect to Commercial Mortgage Pass-Through Certificates, COMM 2015-CCRE25 (the “Agreement”). Capitalized
terms used herein not otherwise defined shall have the meanings assigned in the Agreement.

Pursuant
to Section 10.11 of this Agreement, I, Daniel Bober, Executive Vice President of Commercial Mortgage Services do hereby certify
that:

| | 1. | A review of the activities of the Master Servicer during the period from
August 1, 2015 through December 31, 2015 (the “Reporting Period”), and of its performance per the Agreement during
such period has been made under my supervision, and
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 2. | To the best of my knowledge, based on such review, the Master Servicer has
fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IN
WITNESS WHEREOF, the undersigned has executed this Certificate as of the 4..th..day of March 2016.



Daniel Bober

Executive Vice President 
Wells Fargo Bank







Wells Fargo Bank,
N.A.
This document may contain confidential information and is not available 

online or from the USEPA Docket Center. 

For a copy of the document, please contact Shirley Fan at 

CommercialVesselPermit@epa.gov
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the Balance
Sheet and the Statements of Revenue and Expenses and is qualified in its
entirety by reference to such Report on Form 10-Q.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                       3,107,853
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               5,413,474
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   5,143,425
<TOTAL-LIABILITY-AND-EQUITY>                 5,413,474
<SALES>                                              0
<TOTAL-REVENUES>                               146,094
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                14,059
<LOSS-PROVISION>                             (131,532)
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    29,766
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
# C_2014339EN.01000401.xml

| 29.9.2014 | EN | Official Journal of the European Union | C 339/4 |
| --- | --- | --- | --- |

29.9.2014

EN

Official Journal of the European Union

C 339/4

---

Request for a preliminary ruling from the Oberster Gerichtshof (Austria) lodged on 7 July 2014 — Verein für Konsumenteninformation v A1 Telekom Austria AG

(Case C-326/14)

2014/C 339/04

Language of the case: German

Referring court

Referring court

Oberster Gerichtshof

Parties to the main proceedings

Parties to the main proceedings

Applicant: Verein für Konsumenteninformation

Applicant:

Defendant: A1 Telekom Austria AG

Defendant:

Question referred

Question referred

Is the right, provided for in Article 20(2) of the Universal Service Directive (1), for subscribers to withdraw from their contracts without penalty ‘upon notice of ... modifications in the contractual conditions’ also to be provided for in the case where an adjustment to charges derives from contractual conditions which, from the time when the contract is first concluded, provide that future charges are to be adjusted (upwards or downwards) in accordance with changes in an objective consumer price index reflecting movements in the value of money?

1

---

(1)  Directive 2009/136/EC of the European Parliament and of the Council of 25 November 2009 amending Directive 2002/22/EC on universal service and users’ rights relating to electronic communications networks and services, Directive 2002/58/EC concerning the processing of personal data and the protection of privacy in the electronic communications sector and Regulation (EC) No 2006/2004 on cooperation between national authorities responsible for the enforcement of consumer protection laws (Text with EEA relevance) (OJ 2009 L 337, p. 11).

1

---
#### § 349.10 Ophthalmic astringent.

The active ingredient and its concentration in the product is as follows: Zinc sulfate, 0.25 percent.
<PAGE>   1

                                                                     EXHIBIT 5.1


                         Opinion and Consent of Counsel

                                 April 30, 1999



VoiceStream Wireless Corporation
3650 131st Avenue S.E.
Bellevue, Washington 98006

        Re:    Registration Statement on Form S-8 of VoiceStream Wireless 
               Corporation

Ladies and Gentlemen:

        We have acted as counsel to VoiceStream Wireless Corporation (the
"Company") in connection with the filing of the above-referenced Registration
Statement (the "Registration Statement") relating to the registration of shares
(the "Shares") of Common Stock, no par value per share, of the Company that may
be issued pursuant to the VoiceStream Wireless Corporation 1999 Management
Incentive Stock Option Plan (the "Plan").

        In connection therewith, we have reviewed the Company's Articles of
Incorporation, Bylaws and minutes of appropriate meetings, and we are familiar
with the proceedings to date with respect to the Plan and the proposed issuance
and sale of the Shares and have examined such records, documents and questions
of law, and have satisfied ourselves as to such matters of fact, as we have
considered relevant and necessary as a basis for this opinion.

        Based on the foregoing, it is our opinion that:

        1. The Company is duly incorporated and validly existing under the laws
of the State of Washington.

        2. The Shares, as and when acquired in accordance with the terms and
conditions of the Plan, will be legally issued, fully paid and non-assessable
under the Washington Business Corporation Act when certificates representing the
Shares shall have been duly executed, countersigned and registered and duly
delivered to the purchasers thereof against payment of the agreed consideration
therefor.

        We do not find it necessary for the purposes of this opinion to cover,
and accordingly we express no opinion as to, the application of the securities
or blue sky laws of the various states to the sale of the Shares.


<PAGE>   2

        We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to all references to our firm included in or made a
part of the Registration Statement.

                                            Very truly yours,

                                            PRESTON GATES & ELLIS LLP

                                            By     /s/ G. Scott Greenburg
                                                   G. Scott Greenburg
EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended September 30, 2008 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer. 

 

| Date:

  | November 12, 2008

              |   |
|---------------|---------------------------------------|--------|
|          | /s/ Allan D. Keel                     |   |
| Name:         | Allan D. Keel                         |   |
| Title:        | President and Chief Executive Officer |   |
|          |                                  |   |
|          |                                  |   |

 

A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6375 Patient lubricant. ( a ) *Identification.* A patient lubricant is a device intended for medical purposes that is used to lubricate a body orifice to facilitate entry of a diagnostic or therapeutic device.
( b ) *Classification.* Class I (general controls). Except when the device is a vaginal patient lubricant or an oral lubricant, it is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 66 FR 46952, Sept. 10, 2001; 84 FR 71815, Dec. 30, 2019]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This  schedule  contains  summary  financial   information  extracted  from  the
Consolidated  Statement of Financial  Condition at December 31, 1999 Audited and
the  Consolidated  Statement of Income for the twelve months ended  December 31,
1998 Audited and is  qualified  in its  entirety by reference to such  financial
statements.
</LEGEND>

<S>                                                           <C>
<PERIOD-TYPE>                                                 YEAR
<FISCAL-YEAR-END>                                             DEC-31-1999
<PERIOD-END>                                                  DEC-31-1999
<CASH>                                                        3,377,067
<SECURITIES>                                                          0
<RECEIVABLES>                                                    95,222
<ALLOWANCES>                                                     43,000
<INVENTORY>                                                     356,211
<CURRENT-ASSETS>                                              4,367,323
<PP&E>                                                          519,721
<DEPRECIATION>                                                  125,563
<TOTAL-ASSETS>                                                5,670,245
<CURRENT-LIABILITIES>                                         1,149,129
<BONDS>                                                               0
<PREFERRED-MANDATORY>                                                 0
<PREFERRED>                                                           0
<COMMON>                                                        168,359
<OTHER-SE>                                                    4,352,758
<TOTAL-LIABILITY-AND-EQUITY>                                  5,670,245
<SALES>                                                       1,368,513
<TOTAL-REVENUES>                                              1,722,005
<CGS>                                                         1,410,731
<TOTAL-COSTS>                                                 1,410,731
<OTHER-EXPENSES>                                             12,604,929
<LOSS-PROVISION>                                                      0
<INTEREST-EXPENSE>                                                   28
<INCOME-PRETAX>                                             (12,301,718)
<INCOME-TAX>                                                          0
<INCOME-CONTINUING>                                                   0
<DISCONTINUED>                                                        0
<EXTRAORDINARY>                                                       0
<CHANGES>                                                             0
<NET-INCOME>                                                (12,301,718)
<EPS-BASIC>                                                        (.77)
<EPS-DILUTED>                                                      (.77)



</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3170 Benzodiazepine test system. ( a ) *Identification.* A benzodiazepine test system is a device intended to measure any of the benzodiazepine compounds, sedative and hypnotic drugs, in blood, plasma, and urine. The benzodiazepine compounds include chlordiazepoxide, diazepam, oxazepam, chlorzepate, flurazepam, and nitrazepam. Measurements obtained by this device are used in the diagnosis and treatment of benzodiazepine use or overdose and in monitoring levels of benzodiazepines to ensure appropriate therapy.
( b ) *Classification.* Class II (special controls). A benzodiazepine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
[52 FR 16122, May 1, 1987, as amended at 84 FR 71797, Dec. 30, 2019]
#### Clarence T. Marsala *v.*Valve Corporation of America

*Lawrence J. Merlg,*for the appellee (plaintiff).

*John A. Sabanosh,*for the appellant (defendant).

Argued November 6

decided November 6, 1968

The motion by the plaintiff to dismiss the appeal from the Superior Court in Fairfield County is denied.